Bio-Techne Corp (TECH), a leading biotech firm, has been actively engaged in various business activities, with a continuous flow of updates regarding its
financial performance, new partnerships, and key developments. Recently, it was announced that
TECH will host a conference call to unveil its
Q1 2025 financial results. Prior to this, the firm outperformed the market despite
underlying earnings growth being relatively less than recent stock performance.
Bio-Techne has also established relationships with partners like
Spear Bio and
Thermo Fisher Scientific in recent times, showcasing a proactive approach towards
strategic collaboration. Additionally, the company continues to invest in and highlight its
proprietary technology, which is evident in the announcement of
top-line biomarker data from partner,
Regulus Therapeutics.
Bio-Techne's Q4 profits met expectations, however, revenues fell slightly short of estimates. The
molecular diagnostics firm also filed a significant patent lawsuit against Molecular Instruments. In terms of
acquisitions, the company completed the takeover of
Asuragen and
Lunaphore. Furthermore, Bio-Techne has secured ISO 13485:2016 certification highlighting its commitment to
quality management standards.
Bio-Techne Corp TECH News Analytics from Tue, 04 May 2010 07:00:00 GMT to Sat, 19 Oct 2024 18:34:00 GMT -
Rating 5
- Innovation 7
- Information 7
- Rumor -2
